Despite weathering significant criticism from lawmakers and patient groups over the steep cost of its rare disease med ...
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 6 ...
Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...
The tech giant has released a new line of three 5G industrial edge routers and an IoT gateway series for IoT and edge use cases. Cisco has unveiled a new line of Catalyst industrial edge routers ...
The Cisco Catalyst 8000 Edge Series, which represents a broad portfolio update, offers a ‘massive refresh opportunity’ for channel partners, Cisco tells CRN. Cisco Systems has unveiled a new ...
On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ ... If approved by the FDA, Teva will not market its generic version of Firdapse in the United States before February 25, 2035, unless certain ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback